Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jie Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1794-1360; OpenAlex author ID A5100666927, A5135898681. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 11

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  2. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  3. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  4. Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. Co-author DOI 10.21873/anticanres.15972↗
  5. The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cpr.12805↗
  6. Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer. Co-author DOI 10.1002/pmic.201800451↗
  7. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. Co-author DOI 10.1016/j.canlet.2017.09.018↗
  8. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  9. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Co-author DOI 10.1073/pnas.1611406113↗
  10. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Co-author DOI 10.1158/1078-0432.ccr-14-3382↗
  11. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Co-author DOI 10.1158/1535-7163.mct-14-0420↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul J. Chiao · 9 shared papers, 2015–2026 · strength 1.01
  2. Jianhua Ling · 8 shared papers, 2016–2026 · strength 0.96
  3. Mien‐Chie Hung · 4 shared papers, 2017–2026 · strength 0.56
  4. Ching-Fei Li · 3 shared papers, 2024–2026 · strength 0.51
  5. Anirban Maitra · 3 shared papers, 2024–2026 · strength 0.51
  6. Kenei Furukawa · 3 shared papers, 2020–2024 · strength 0.44
  7. Haoqiang Ying · 3 shared papers, 2017–2026 · strength 0.42
  8. Huamin Wang · 3 shared papers, 2017–2026 · strength 0.41
  9. Lu Yu · 4 shared papers, 2017–2024 · strength 0.38
  10. Yongkun Wei · 2 shared papers, 2024–2026 · strength 0.37
  11. Ying‐Nai Wang · 2 shared papers, 2024–2026 · strength 0.37
  12. Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
  13. Dihua Yu · 2 shared papers, 2024–2026 · strength 0.37
  14. Peng Huang · 3 shared papers, 2015–2024 · strength 0.25
  15. Huai‐Qiang Ju · 4 shared papers, 2015–2017 · strength 0.21
  16. Cheng‐Wei Chou · 1 shared paper, 2026 · strength 0.21
  17. Wantong Yao · 1 shared paper, 2026 · strength 0.21
  18. Jun Yao · 2 shared papers, 2017–2024 · strength 0.20
  19. Jason B. Fleming · 2 shared papers, 2016–2024 · strength 0.19
  20. Zhuonan Zhuang · 3 shared papers, 2016–2017 · strength 0.16
  21. Ping Chen · 1 shared paper, 2024 · strength 0.14
  22. Ya’an Kang · 1 shared paper, 2024 · strength 0.14
  23. Qian Huang · 1 shared paper, 2024 · strength 0.14
  24. Jun Zhao · 1 shared paper, 2024 · strength 0.14
  25. Wenjuan Yin · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.